HRT vs Natural Remedies for Menopause: What the Research Says

If there's one question that comes up repeatedly in menopause forums, in doctors' offices, and between women who are quietly comparing notes, it's this: should I do HRT or go natural?

The conversation has been dominated — and distorted — by a single study from 2002 that led millions of women to stop hormone therapy and has taken two decades to fully correct. Today, the research landscape looks very different. Understanding it clearly is one of the most important health decisions many women will make in their 40s and 50s.

The Study That Changed Everything (and Why It's Been Largely Corrected)

In 2002, the Women's Health Initiative (WHI) published preliminary results from a large hormone therapy trial. The finding: combined estrogen and progestin increased risk of breast cancer, heart disease, stroke, and blood clots. The media coverage was immediate and alarming. Millions of women stopped HRT. Prescriptions collapsed. The medical consensus shifted dramatically away from hormone therapy for menopause.

What the initial coverage largely buried: the study had significant methodological limitations. The participants were much older than typical HRT candidates (average age 63, many years post-menopause rather than in the early transition). The form of progestin used (medroxyprogesterone acetate) is not the same as the micronized progesterone used in contemporary practice. The doses were higher than what most women need.

Subsequent re-analyses — including a 2020 analysis of the original WHI data published in the journal Fertility and Sterility — found that for women who start HRT within 10 years of menopause onset, at standard doses, the cardiovascular and other risks are significantly lower, and benefits are more pronounced. The concept of the "timing hypothesis" — that starting HRT early in the transition is protective, while starting late may carry more risk — is now well-supported by evidence.

The current medical consensus from the American College of Obstetricians and Gynecologists (ACOG), the North American Menopause Society (NAMS / The Menopause Society), and the Endocrine Society: for most healthy women under 60 experiencing moderate to severe menopause symptoms, the benefits of hormone therapy outweigh the risks.

What Hormone Therapy Actually Does

Hormone therapy for menopause comes in two main types:

Estrogen-only therapy (ET) is used in women who have had a hysterectomy — there's no need for progesterone to protect the uterus if there's no uterus. Estrogen alone is associated with lower breast cancer risk than no therapy (yes, lower — the baseline comparison that matters).

Combined estrogen-progestogen therapy (EPT) is used in women with an intact uterus. Progestogen (either progestin or bioidentical micronized progesterone) is required to prevent estrogen-induced endometrial hyperplasia, which increases uterine cancer risk. The choice of progestogen matters: micronized progesterone (brand name Prometrium, or generic) appears to have a more favorable safety profile than synthetic progestins like medroxyprogesterone acetate.

HRT addresses the root cause of most menopause symptoms — estrogen withdrawal — rather than managing individual symptoms after they appear. It is the most effective treatment available for vasomotor symptoms (hot flashes, night sweats), and it also improves sleep, mood, sexual function, and bone density. For women with premature ovarian insufficiency (menopause before age 40), HRT has additional health-protective benefits beyond symptom management.

When HRT Is Not an Option

There are some situations where HRT is genuinely contraindicated, or where women prefer to avoid it. These include:

• Hormone receptor-positive breast cancer — Estrogen can fuel recurrence in some breast cancer types. Most oncologists advise against systemic estrogen therapy. This is not a preference — it's a medical contraindication.
• Active liver disease or history of estrogen-sensitive blood clots — These are relative contraindications requiring specialist assessment.
• Personal or strong family history of breast cancer — This is more nuanced. For women with BRCA mutations who have not had breast cancer, the risk-benefit calculation is individual. Women with a family history but no personal history of breast cancer are generally candidates for HRT after thorough discussion with their provider. Each case is different.
• Women who prefer to avoid hormones — This is a valid choice. Not everyone wants hormone therapy, and not wanting it is legitimate regardless of what the research says about safety.

Non-Hormonal Options That Actually Work

For women who cannot or choose not to use HRT, there are effective non-hormonal alternatives — a landscape that has expanded considerably in the last few years:

Veozah (fezolinetant) — Approved by the FDA in 2023, this is the first non-hormonal drug specifically designed to treat hot flashes. It works by blocking the neurokinin B (NKB) signaling pathway in the brain, which is the same pathway that causes hot flashes. Clinical trials showed it reduces hot flash frequency by about 60-65% — roughly comparable to lower-dose HRT. It does not affect estrogen levels, so it does not carry the hormone-related risks. It requires liver monitoring.

SSRIs and SNRIs — Originally developed as antidepressants, these medications have been found to reduce hot flash frequency by about 50-60% in multiple studies. Paroxetine (Brisdelle/Paxil) is the only FDA-approved SSRI for hot flashes specifically. Venlafaxine (Effexor), an SNRI, is also commonly used. Side effects include nausea, sexual dysfunction, and weight changes. Low-dose SSRIs also have modest mood benefits, which many women appreciate during menopause.

Gabapentin — Originally an anticonvulsant, gabapentin is frequently prescribed off-label for hot flashes and night sweats, particularly when they disrupt sleep. It reduces hot flash frequency for many women. Side effects include dizziness, grogginess, and weight gain. A newer extended-release formulation (gabapentin enacarbil, Horizant) may have a more favorable side effect profile.

Lifestyle modifications — These are worth mentioning because they're genuinely helpful, though not as potent as medication: layering clothing, keeping bedrooms cool, avoiding known triggers (spicy food, alcohol, caffeine), regular aerobic exercise (reduces hot flash severity even if not frequency), and stress reduction techniques (mindfulness, CBT) all show measurable benefit in controlled trials. They're not a substitute for medication when symptoms are moderate to severe, but they're a real complement to any treatment approach.

Phytoestrogens and supplements — The evidence for most supplements is weak to nonexistent. Soy isoflavones show modest benefit for hot flashes in some trials; black cohosh has minimal evidence beyond placebo; evening primrose oil, red clover, and most other herbal menopause supplements have not demonstrated consistent benefit in randomized trials. If you want to try phytoestrogens, food sources (tofu, tempeh, flaxseed) are safer and better-supported than supplements.

What About Vaginal Estrogen?

Vaginal estrogen — creams, rings, or tablets applied directly to vaginal tissue — is different from systemic hormone therapy and deserves separate mention. It treats genitourinary syndrome of menopause (GSM): vaginal dryness, painful intercourse, urinary urgency, and recurrent UTIs that don't respond to other treatments.

Vaginal estrogen is applied locally and absorbs minimally into the bloodstream. Studies show estrogen levels in women using vaginal estrogen are barely distinguishable from baseline. It is considered safe for most women, including many women with a history of breast cancer — but that decision requires a conversation with your oncologist.

The stigma around "any estrogen" leads many women to suffer with GSM symptoms for years when treatment is available and effective. This is an area where patient hesitation and provider unfamiliarity with current guidelines cause real harm.

The Honest Answer to "Which Is Better?"

There is no universally correct answer. Here's what the evidence does support:

For most healthy women under 60 with moderate to severe symptoms, HRT is the most effective option and the one with the most favorable benefit-risk profile when started within the timing window. The fear around breast cancer risk — which is real but small — needs to be put in context: the increased risk from combined HRT is approximately 8 additional cases of breast cancer per 10,000 women per year. Drinking one glass of wine daily carries approximately the same risk. Being overweight after menopause carries a larger risk than that.

For women who can't use HRT or don't want to, Veozah, SSRIs/SNRIs, or gabapentin are legitimate, evidence-based alternatives with meaningful efficacy. They don't work as well as well-matched HRT, but they work better than nothing.

For all women with GSM symptoms, vaginal estrogen is underused, effective, and far safer than its reputation suggests.

What matters is making this decision with current information — not based on 2002 headlines, not based on fear, and not based on an assumption that "natural" always means "safer." It doesn't.

How PauseKit Can Help You Decide

The choice between HRT, non-hormonal treatment, or a combination approach is deeply personal and deserves individual attention. Before talking to your doctor, it helps to have a clear picture of what you're experiencing — not just "I have hot flashes" but "I've had X hot flashes in the last week, Y night sweats, my sleep score is Z, and my mood is affected in this specific way."

PauseKit's symptom tracker captures the data you need to have a more specific conversation with your provider. And if you're trying to understand whether HRT is right for you, take our HRT readiness quiz — it walks you through the key questions to consider, based on your symptoms, health history, and what you want from treatment.